IC 702 is a next generation broad-spectrum ocular antibiotic with a unique MOA designed to be highly effective against resistant bacteria. It has a greater potency compared to currently marketed ocular antibiotics. It maintains potency against fluoroquinolone-resistant and multi-drug resistant clinical isolates, including methicillin-resistant staphylococcus aureus (MRSA), by uniquely targeting topoisomerase IV, DNA gyrase, and DNA primase.